Business Wire

CGTN:Why Did Xi Jinping Make Fujian His First Stop After Five-year Plan Approval?

Share

As China's latest medium and long-term economic and social development plan was just approved at the country's top legislature, President Xi Jinping has left Beijing for his first inspection trip to east China's Fujian Province after the Two Sessions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323006017/en/

Xi's visits to an ecological tea garden and the Wuyishan National Park during the inspection show the importance he attaches to green, ecological development, which was also stressed in China's road map for development for the next five years and beyond.

Wuyi Mountain and ecological protection

Standing in the suburbs of Wuyishan City, Mount Wuyi entered UNESCO's list of World Heritage Sites in 1999. It covers an area of over 630 square kilometers and numerous types of tea are produced there.

Visiting mountains is usually arranged in Xi's inspection tours as construction of ecological civilization has always been stressed by the president.

In April 2020, Xi's first stop was also to visit the mountains. He went directly to the Qinling Mountains during his inspection in northwest China's Shaanxi Province to learn about ecological protection, urging officials to be guardians of ecological environment.

In August 2019, he went to northwest China's Gansu Province and visited the Qilian Mountains, underlining ecological protection as a national strategy.

On Monday, during his visit to the Wuyishan National Park, he encountered a group of tourists. "You can enjoy the mountain scenery in Wuyishan and enjoy the seascape in Xiamen City," he told the group.

Xi also visited the park's intelligent management center, where all the weather monitoring and services for biological resources within the park are conducted.

During the just-concluded Two Sessions, he said top-level design and comprehensive measures are needed to protect the ecosystems in mountains, rivers, forests, farmlands, lakes, grasslands and deserts.

Tea industry and rural vitalization

"In the past, the tea industry was a pillar in your fight against poverty, and it should become a pillar industry of rural vitalization in the future," Xi said on Monday at the tea garden.

He called for efforts to better cultivate a vibrant tea industry that takes advantage of Mount Wuyi's long history of tea culture, suitable climate, rich tea resources and the support of science and technology.

Shaking off poverty is not the finish line but the starting line of a new life and new endeavor, Xi said in February after announcing that China has secured a "complete victory" in its fight against poverty, urging efforts to effectively integrate the consolidation of poverty alleviation achievements and rural vitalization.

China detailed plans to fully promote the strategy of rural vitalization in the Chinese leadership's proposals for formulating the 14th Five-Year Plan (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035.

Under this development blueprint, the country will push the development of industries with distinctive rural characteristics, cultivate new industries and modes of business, and encourage entrepreneurship and innovation in rural areas.

During his stop at the tea garden, Xi was pleased when hearing that the quality of tea was greatly improved through ecological planting in recent years, under the guidance of the team of technology commissioners.

Agricultural talents, also called "technological commissioners," was an idea introduced by Xi, the then governor to Fujian Province in a 2002 article, which called for bonding officials and farmers.

The president has stressed the role of science and technology in poverty alleviation and rural revitalization many times, calling for efforts to promote science and technological innovation in agriculture to support all-around rural revitalization.

During the inspection, Xi also visited a park dedicated to Zhu Xi, a renowned Chinese philosopher in the 12th century, in Nanping City on Monday afternoon, learning about local efforts to pass on traditional culture.

https://news.cgtn.com/news/2021-03-23/Xi-Jinping-makes-Fujian-his-first-stop-after-Five-Year-Plan-approval-YRH8REcXW8/index.html

Contact information

Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent12.4.2021 17:04:00 CEST | Press release

Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset in the company’s DNA damage response (DDR) inhibitor program and one of the most advanced ATR inhibitors in oncology clinical development industry-wide. Results from a Phase II proof-of-concept study conducted by the US National Cancer Institute (NCI) (NCT02487095)* and published in Cancer Cell showed that berzosertib in combination with the chemotherapy topotecan resulted in an objective response rate (ORR) of 36% among patients with relapsed small cell lung cancer (SCLC), including durable responses among a majority of responding patients with platinum-resistant disease.1 The NCI is also conducting a separate Phase II trial of berzosertib in combination with topotecan versus topotecan monotherapy in SCLC that has relapsed (NCT03896503)* which

Loomis Sayles Welcomes Susan Sieker as Chief Financial Officer12.4.2021 16:15:00 CEST | Press release

Loomis, Sayles & Company, an affiliate of Natixis Investment Managers, announced today that Susan Sieker has joined Loomis Sayles as executive vice president and chief financial officer (CFO). She also joins the Loomis Sayles Board of Directors. Susan reports to Kevin Charleston, chairman and chief executive officer of Loomis Sayles, and will oversee the finance organization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005613/en/ Susan joins Loomis Sayles from Cambridge Associates, where she was the chief financial officer and oversaw financial planning and analysis, treasury, accounting operations, financial reporting, payroll and taxes. Prior to joining Cambridge Associates in 2012, Susan served in a variety of finance and risk leadership roles at Brinker International, including vice president and treasurer, vice president of global infrastructure, vice president of benefits, vice president of business assurance

Alira Health Strengthens Its Growth Strategy With a $35M Funding, Led by Creadev12.4.2021 15:00:00 CEST | Press release

Alira Health (www.alirahealth.com), a leading international advisory firm dedicated to advancing healthcare and life sciences, announced it has closed a $35M equity financing led by Creadev, an evergreen investment company backed by the Mulliez family. This new partnership will help accelerate the firm’s growth strategy, focused on merging pharmaceutical, medical and digital technologies development with medical care through a patient-centric approach. “I would like to thank our team of investors for joining our mission to enable healthcare transformation. Their investment positions us to change the way life sciences advisory services are delivered,” said Gabriele Brambilla, Chief Executive Officer and Co-Founder of Alira Health. “We are building a powerful continuum of services that spans the product and solutions development life cycle, supported by the recent additions of our patient engagement, real-world evidence and advanced analytics practices. This financing allows us to advanc

KD Pharma Acquires Phytoextract and CBD Manufacturing Assets12.4.2021 14:45:00 CEST | Press release

The KD Pharma Group has acquired the manufacturing assets of a Swiss-based cannabinoid manufacturer. The assets give KD Pharma access to technology for producing Active Pharmaceutical Ingredients (APIs) based on phytocannabinoids and other plant extracts. The technology further expands KD’s lipid technology portfolio and can be used in combination with KD’s other fractionation and separation technologies. “KD Pharma is a leader in lipid technology focused primarily on omega-3s, but our technology suite has applications in other lipid sources like cannabinoids,” said Oscar Groet, CEO of the KD Pharma Group. “We have committed to expanding our technology portfolio to develop APIs from cannabinoids and plant extracts,” Groet continued, “and these assets give KD Pharma additional pathways to develop new products for this emerging market.” The KD Pharma Group has also licensed a novel extraction method from Herbolea Biotech S.r.l. and expects to have a complete, licensed cGMP manufacturing

Globality and BT Sourced Announce New Partnership to Unleash the Power of Procurement12.4.2021 14:00:00 CEST | Press release

Through a new partnership with Globality and BT’s new procurement company, BT Sourced, BT launched Globality’s AI-powered Smart Sourcing® Platform to transform how BT employees source and procure services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005173/en/ “BT’s changing and so is procurement. Digitization is the driving force for long-term growth and value to the BT customer and operating model,” said Cyril Pourrat, Chief Procurement Officer, BT. “Partnering with Globality will help us to embrace digital technology and simplify our processes.” “Having immediate access to our current suppliers and Globality’s diverse global network will bring agility and new value to our teams,” added Pourrat. BT now uses Globality’s AI advisor, Glo™, to quickly and easily source the best suppliers for consulting, marketing, IT, HR, legal and other service categories. “BT is revolutionizing the way it sources services in order t

FLIR Wins DARPA Contract Worth Up to $20.5M to Develop Revolutionary New Protective Fabrics for Chem-Bio Defense12.4.2021 14:00:00 CEST | Press release

FLIR Systems, Inc. (NASDAQ: FLIR) announced it has won a contract with the Defense Advanced Research Projects Agency (DARPA) to rapidly develop novel fabrics with embedded catalysts and chemistries that can fight and reduce chemical and biological threats upon contact. The revolutionary fabrics will be incorporated into protective suits and other equipment such as boots, gloves, and eye protection that can be worn by troops on the battlefield, medical experts, healthcare workers, and more. FLIR received $11.2 million in initial funding for the potential five-year effort worth up to $20.5 million, including options. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005140/en/ The Personalized Protective Biosystems (PPB) program will create fabrics with built-in ability to fight chemical and biological agents, from VX to chlorine gas to Ebola virus. The revolutionary fabrics being developed by FLIR Systems will be incorpora

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis12.4.2021 14:00:00 CEST | Press release

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Vivet Therapeutics (“Vivet”) announced today an agreement whereby Mirum has the exclusive option to develop and subsequently commercialize Vivet’s two proprietary AAV gene therapy programs for progressive familial intrahepatic cholestasis (PFIC), subtypes 3 and 2. The two programs, VTX-803 and VTX-802, are currently being evaluated in preclinical studies by Vivet, a privately-held gene therapy biotechnology company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005354/en/ Under the terms of the agreement, Vivet will continue to advance the preclinical studies for VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively. Mirum has the exclusive option to license the programs after which Mirum would lead the clinical development and any future commercialization of the programs. Until that time, Mirum will provide funding to support the continued research and development costs